TCL Archive Progression-free survival as a primary endpoint for drug approval requires prospective planning, FDA’s Pazdur says. May 7, 2004
TCL Archive Slow Accruing Trials Should Be Removed From High Priority Program, Broder Says October 2, 1992
TCL Archive After 30 Years As NCI-Designated Center, Vermont Cancer Center Loses Core Grant. November 14, 2008
TCL Archive President’s Budget: $64 Million Cut for NCI, No Start On Year 2000 goals, Drop 240 Grants In 1985 February 8, 1985
